Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Double-blind, Placebo-controlled, 2-period, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients With Inherited Erythromelalgia.

NCT01090622 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.

NCT NCT01090622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01090622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Double-blind, Placebo-controlled, 2-period, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients With Inherited Erythromelalgia.
Lead sponsor
Xenon Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2010
Completion date
September 30, 2010
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inherited erythromelalgia, primary erythromelalgia